List of Tables
Table 1. Global Beta-lactam and Beta-lactamase Inhibitors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Beta-lactam and Beta-lactamase Inhibitors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Beta-lactam and Beta-lactamase Inhibitors Market Competitive Situation by Manufacturers in 2025
Table 4. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) of Key Manufacturers (2021–2026)
Table 5. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Beta-lactam and Beta-lactamase Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Beta-lactam and Beta-lactamase Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Beta-lactam and Beta-lactamase Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Product Types and Applications
Table 12. Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Beta-lactam and Beta-lactamase Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Beta-lactam and Beta-lactamase Inhibitors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (M Units), 2021–2026
Table 18. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region (2021–2026)
Table 19. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (M Units), 2027–2032
Table 20. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region (2027–2032)
Table 21. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 22. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Region (2021–2026)
Table 23. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 24. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Region (2027–2032)
Table 25. North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (M Units), 2021–2026
Table 27. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (M Units), 2027–2032
Table 28. North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 29. North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (M Units), 2021–2026
Table 32. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (M Units), 2027–2032
Table 33. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region (M Units), 2021–2026
Table 37. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region (M Units), 2027–2032
Table 38. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (M Units), 2021–2026
Table 42. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (M Units), 2027–2032
Table 43. Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (M Units), 2021–2026
Table 47. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (M Units), 2027–2032
Table 48. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 50. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) by Type (2021–2026)
Table 51. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) by Type (2027–2032)
Table 52. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2021–2026)
Table 53. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2027–2032)
Table 54. Global Beta-lactam and Beta-lactamase Inhibitors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Beta-lactam and Beta-lactamase Inhibitors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2021–2026)
Table 57. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2027–2032)
Table 58. Global Beta-lactam and Beta-lactamase Inhibitors Price (US$/Unit) by Type (2021–2026)
Table 59. Global Beta-lactam and Beta-lactamase Inhibitors Price (US$/Unit) by Type (2027–2032)
Table 60. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) by Application (2021–2026)
Table 61. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) by Application (2027–2032)
Table 62. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2021–2026)
Table 63. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2027–2032)
Table 64. Global Beta-lactam and Beta-lactamase Inhibitors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Beta-lactam and Beta-lactamase Inhibitors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2021–2026)
Table 67. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2027–2032)
Table 68. Global Beta-lactam and Beta-lactamase Inhibitors Price (US$/Unit) by Application (2021–2026)
Table 69. Global Beta-lactam and Beta-lactamase Inhibitors Price (US$/Unit) by Application (2027–2032)
Table 70. Pfizer Company Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Pfizer Beta-lactam and Beta-lactamase Inhibitors Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Novartis (Sandoz) Company Information
Table 76. Novartis (Sandoz) Description and Business Overview
Table 77. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product
Table 79. Novartis (Sandoz) Recent Developments/Updates
Table 80. TEVA Company Information
Table 81. TEVA Description and Business Overview
Table 82. TEVA Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. TEVA Beta-lactam and Beta-lactamase Inhibitors Product
Table 84. TEVA Recent Developments/Updates
Table 85. Merck & Co. Company Information
Table 86. Merck & Co. Description and Business Overview
Table 87. Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Product
Table 89. Merck & Co. Recent Developments/Updates
Table 90. AbbVie (Allergan) Company Information
Table 91. AbbVie (Allergan) Description and Business Overview
Table 92. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product
Table 94. AbbVie (Allergan) Recent Developments/Updates
Table 95. Sumitomo Dainippon Company Information
Table 96. Sumitomo Dainippon Description and Business Overview
Table 97. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product
Table 99. Sumitomo Dainippon Recent Developments/Updates
Table 100. Hikma Company Information
Table 101. Hikma Description and Business Overview
Table 102. Hikma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Hikma Beta-lactam and Beta-lactamase Inhibitors Product
Table 104. Hikma Recent Developments/Updates
Table 105. Aurobindo Pharma Company Information
Table 106. Aurobindo Pharma Description and Business Overview
Table 107. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product
Table 109. Aurobindo Pharma Recent Developments/Updates
Table 110. Wockhardt Company Information
Table 111. Wockhardt Description and Business Overview
Table 112. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product
Table 114. Wockhardt Recent Developments/Updates
Table 115. Lupin Limited Company Information
Table 116. Lupin Limited Description and Business Overview
Table 117. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product
Table 119. Lupin Limited Recent Developments/Updates
Table 120. Fresenius Kabi Company Information
Table 121. Fresenius Kabi Description and Business Overview
Table 122. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product
Table 124. Fresenius Kabi Recent Developments/Updates
Table 125. B. Braun Company Information
Table 126. B. Braun Description and Business Overview
Table 127. B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. B. Braun Beta-lactam and Beta-lactamase Inhibitors Product
Table 129. B. Braun Recent Developments/Updates
Table 130. USantibiotics Company Information
Table 131. USantibiotics Description and Business Overview
Table 132. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product
Table 134. USantibiotics Recent Developments/Updates
Table 135. Qilu Pharmaceutical Company Information
Table 136. Qilu Pharmaceutical Description and Business Overview
Table 137. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product
Table 139. Qilu Pharmaceutical Recent Developments/Updates
Table 140. ACS Dobfar Company Information
Table 141. ACS Dobfar Description and Business Overview
Table 142. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product
Table 144. ACS Dobfar Recent Developments/Updates
Table 145. Nichi-Iko (Sagent) Company Information
Table 146. Nichi-Iko (Sagent) Description and Business Overview
Table 147. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product
Table 149. Nichi-Iko (Sagent) Recent Developments/Updates
Table 150. Antibiotice Company Information
Table 151. Antibiotice Description and Business Overview
Table 152. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product
Table 154. Antibiotice Recent Developments/Updates
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Beta-lactam and Beta-lactamase Inhibitors Distributors List
Table 158. Beta-lactam and Beta-lactamase Inhibitors Customers List
Table 159. Beta-lactam and Beta-lactamase Inhibitors Market Trends
Table 160. Beta-lactam and Beta-lactamase Inhibitors Market Drivers
Table 161. Beta-lactam and Beta-lactamase Inhibitors Market Challenges
Table 162. Beta-lactam and Beta-lactamase Inhibitors Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
Table 166. Authors List of This Report
List of Figures
Figure 1. Product Picture of Beta-lactam and Beta-lactamase Inhibitors
Figure 2. Global Beta-lactam and Beta-lactamase Inhibitors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Type: 2025 & 2032
Figure 4. Penicillins Product Picture
Figure 5. Cephalosporins Product Picture
Figure 6. Carbapenems Product Picture
Figure 7. Monobactams Product Picture
Figure 8. Combinations Product Picture
Figure 9. Global Beta-lactam and Beta-lactamase Inhibitors Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Application: 2025 & 2032
Figure 11. Oral
Figure 12. Intravenous
Figure 13. Global Beta-lactam and Beta-lactamase Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Beta-lactam and Beta-lactamase Inhibitors Market Size (US$ Million), 2021–2032
Figure 15. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), 2021–2032
Figure 16. Global Beta-lactam and Beta-lactamase Inhibitors Average Price (US$/Unit), 2021–2032
Figure 17. Beta-lactam and Beta-lactamase Inhibitors Report Years Considered
Figure 18. Beta-lactam and Beta-lactamase Inhibitors Sales Share by Manufacturers in 2025
Figure 19. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Beta-lactam and Beta-lactamase Inhibitors Players: Market Share by Revenue in Beta-lactam and Beta-lactamase Inhibitors in 2025
Figure 21. Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2021–2032)
Figure 24. North America Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2021–2032)
Figure 25. United States Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2021–2032)
Figure 28. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2021–2032)
Figure 29. Germany Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Region (2021–2032)
Figure 36. China Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Indonesia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Thailand Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Malaysia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2021–2032)
Figure 46. Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2021–2032)
Figure 47. Mexico Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Brazil Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Argentina Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2021–2032)
Figure 51. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2021–2032)
Figure 52. Turkey Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Saudi Arabia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. UAE Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Global Sales Market Share of Beta-lactam and Beta-lactamase Inhibitors by Type (2021–2032)
Figure 56. Global Revenue Market Share of Beta-lactam and Beta-lactamase Inhibitors by Type (2021–2032)
Figure 57. Global Beta-lactam and Beta-lactamase Inhibitors Price (US$/Unit) by Type (2021–2032)
Figure 58. Global Sales Market Share of Beta-lactam and Beta-lactamase Inhibitors by Application (2021–2032)
Figure 59. Global Revenue Market Share of Beta-lactam and Beta-lactamase Inhibitors by Application (2021–2032)
Figure 60. Global Beta-lactam and Beta-lactamase Inhibitors Price (US$/Unit) by Application (2021–2032)
Figure 61. Beta-lactam and Beta-lactamase Inhibitors Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
